4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Body Mass Index Change in Autism Spectrum Disorders: Comparison of Treatment with Risperidone and Aripiprazole

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objective: The purpose of this study was to assess change in body mass index (BMI) and age- and gender-adjusted BMI Z-score in subjects ages 2–20 years with autism spectrum disorders (ASD), who were treated longitudinally with risperidone or aripiprazole at a tertiary care ASD clinic.

          Method: As part of a larger project involving longitudinal drug treatment data in ASD, detailed demographic and treatment data were collected for 142 subjects ages 2–20 years who had been started on risperidone or aripiprazole for treatment of irritability. Mean age at start of treatment, treatment duration, final Clinical Global Impressions-Improvement Scale score, BMI change per year of treatment, and BMI Z-score change per year of treatment (primary outcome measure) were calculated for each drug treatment group. Group means were compared using t tests and Wilcoxon rank sum tests.

          Results: There was a statistically significant BMI and BMI Z-score increase in the risperidone and aripiprazole treatment groups individually. No statistically significant difference between the two treatment groups was noted in mean BMI change per year of treatment or BMI Z-score change per year of treatment.

          Conclusions: In our review of long-term naturalistic treatment of irritability using risperidone versus aripiprazole in persons with ASD, a significant increase in both BMI and age- and gender-adjusted BMI Z-score was noted for each treatment group. No significant difference in BMI or BMI Z-score change was noted when the two treatment groups were compared. We conclude that in our patient population at a tertiary care ASD clinic, the effects of risperidone and aripiprazole on body weight gain in naturalistic long-term treatment are no different.

          Related collections

          Author and article information

          Journal
          J Child Adolesc Psychopharmacol
          J Child Adolesc Psychopharmacol
          cap
          Journal of Child and Adolescent Psychopharmacology
          Mary Ann Liebert, Inc. (140 Huguenot Street, 3rd FloorNew Rochelle, NY 10801USA )
          1044-5463
          1557-8992
          01 March 2014
          01 March 2014
          : 24
          : 2
          : 78-82
          Affiliations
          [ 1 ] Cincinnati Children's Hospital Medical Center , Cincinnati, Ohio.
          [ 2 ] Indiana University School of Medicine , Indianapolis, Indiana.
          [ 3 ] University of Cincinnati , Cincinnati, Ohio. Dr. McDougle is affiliated with
          [ 4 ] Harvard Medical School and the Lurie Center for Autism , Lexington, Massachusetts.
          Author notes
          Address correspondence to: Logan K. Wink, MD, Cincinnati Children's Hospital Medical Center 3333 Burnet Ave. MLC 4002, Cincinnati, OH 45229, E-mail: Logan.Wink@ 123456cchmc.org
          Article
          PMC5248544 PMC5248544 5248544 10.1089/cap.2013.0099
          10.1089/cap.2013.0099
          5248544
          24564519
          c828d335-1847-413c-8a32-5d486373f86e
          Copyright 2014, Mary Ann Liebert, Inc.
          History
          Page count
          Tables: 4, References: 22, Pages: 5
          Categories
          Original Articles

          Comments

          Comment on this article